Doug Manion, Aclaris Therapeutics CEO

Aclaris los­es 85% of share val­ue af­ter an­oth­er PhII set­back in in­flam­ma­to­ry con­di­tion

Aclaris Ther­a­peu­tics’ lead drug has failed an­oth­er mid-stage test, mark­ing the biotech’s sec­ond ma­jor set­back this year and the au­toim­mune treat­ment’s fi­nal shot in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.